Article Cited by others


Androgen receptor signaling in prostate cancer development and progression

Lonergan Peter E, Tindall Donald J

Year : 2011| Volume: 10| Issue : 1 | Page no: 20-20

   This article has been cited by
1 SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer
J. Hoefer,J. Kern,P. Ofer,I. E. Eder,G. Schafer,D. Dietrich,G. Kristiansen,S. Geley,J. Rainer,E. Gunsilius,H. Klocker,Z. Culig,M. Puhr
Endocrine Related Cancer. 2014; 21(2): 175
[Pubmed]  [Google Scholar] [DOI]
2 Seasonal variation of urinary microRNA expression in male goats (Capra hircus) as assessed by next generation sequencing
Kristy M. Longpre,Noah S. Kinstlinger,Edward A. Mead,Yongping Wang,Austin P. Thekkumthala,Katherine A. Carreno,Azra Hot,Jennifer M. Keefer,Luke Tully,Larry S. Katz,Andrzej Z. Pietrzykowski
General and Comparative Endocrinology. 2014;
[Pubmed]  [Google Scholar] [DOI]
3 Network analysis of ChIP-Seq data reveals key genes in prostate cancer
Yu Zhang,Zhen Huang,Zhiqiang Zhu,Jianwei Liu,Xin Zheng,Yuhai Zhang
European Journal of Medical Research. 2014; 19(1)
[Pubmed]  [Google Scholar] [DOI]
4 The pluripotency factor Nanog is directly upregulated by the Androgen Receptor in prostate cancer cells
Steven Kregel,Russell Z. Szmulewitz,Donald J. Vander Griend
The Prostate. 2014; 74(15): 1530
[Pubmed]  [Google Scholar] [DOI]
5 Role of miRNALet-7and Its Major Targets in Prostate Cancer
Siegfried Wagner,Anaclet Ngezahayo,Hugo Murua Escobar,Ingo Nolte
BioMed Research International. 2014; 2014: 1
[Pubmed]  [Google Scholar] [DOI]
6 Negative Regulation of the Androgen Receptor Gene Through a Primate-Specific Androgen Response Element Present in the 5' UTR
Colin W. Hay,Kate Watt,Irene Hunter,Derek N. Lavery,Alasdair MacKenzie,Iain J. McEwan
Hormones and Cancer. 2014;
[Pubmed]  [Google Scholar] [DOI]
7 Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers
Mani Roshan-Moniri,Michael Hsing,Miriam S. Butler,Artem Cherkasov,Paul S. Rennie
Cancer Treatment Reviews. 2014;
[Pubmed]  [Google Scholar] [DOI]
8 ETS fusion genes in prostate cancer
D. Gasi Tandefelt,J. Boormans,K. Hermans,J. Trapman
Endocrine Related Cancer. 2014; 21(3): R143
[Pubmed]  [Google Scholar] [DOI]
9 Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator
Pekka K. Poutiainen,Tuulia Huhtala,Tiina Jääskeläinen,Aleksanteri Petsalo,Jenni Küblbeck,Sanna Kaikkonen,Jorma J. Palvimo,Hannu Raunio,Ale Närvänen,Mikael Peräkylä,Risto O. Juvonen,Paavo Honkakoski,Reino Laatikainen,Juha T. Pulkkinen
Molecular and Cellular Endocrinology. 2014; 387(1-2): 8
[Pubmed]  [Google Scholar] [DOI]
10 A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A)
Donita J. Africander,Karl-Heinz Storbeck,Janet P. Hapgood
The Journal of Steroid Biochemistry and Molecular Biology. 2014;
[Pubmed]  [Google Scholar] [DOI]
11 Good guy or bad guy: the opposing roles of microRNA 125b in cancer
Julia Banzhaf-Strathmann,Dieter Edbauer
Cell Communication and Signaling. 2014; 12(1): 30
[Pubmed]  [Google Scholar] [DOI]
12 Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer
D. Wu,B. Sunkel,Z. Chen,X. Liu,Z. Ye,Q. Li,C. Grenade,J. Ke,C. Zhang,H. Chen,K. P. Nephew,T. H.- M. Huang,Z. Liu,V. X. Jin,Q. Wang
Nucleic Acids Research. 2014;
[Pubmed]  [Google Scholar] [DOI]
13 Prostate cancer: the need for biomarkers and new therapeutic targets
Juliana Felgueiras,Joana Vieira Silva,Margarida Fardilha
Journal of Zhejiang University SCIENCE B. 2014; 15(1): 16
[Pubmed]  [Google Scholar] [DOI]
14 Exercise Does Not Counteract the Effects of a “Westernized” Diet on Prostate Cancer Xenografts
Avi D. Vandersluis,Natalie A. Venier,Alexandra J. Colquhoun,Linda Sugar,Michael Pollak,Alex Kiss,Neil E. Fleshner,Laurence H. Klotz,Vasundara Venkateswaran
The Prostate. 2013; 73(11): 1223
[Pubmed]  [Google Scholar] [DOI]
15 Androgen receptor co-regulatory networks in castration-resistant prostate cancer
Y. Y. Sung,E. Cheung
Endocrine Related Cancer. 2013; 21(1): R1
[Pubmed]  [Google Scholar] [DOI]
16 Chemotherapy and Targeted Therapies: Are We Making Progress in Castrate-Resistant Prostate Cancer?
Jean Hoffman-Censits,Maofu Fu
Seminars in Oncology. 2013; 40(3): 361
[Pubmed]  [Google Scholar] [DOI]
17 SMYD3 as an Oncogenic Driver in Prostate Cancer by Stimulation of Androgen Receptor Transcription
C. Liu,C. Wang,K. Wang,L. Liu,Q. Shen,K. Yan,X. Sun,J. Chen,J. Liu,H. Ren,H. Liu,Z. Xu,S. Hu,D. Xu,Y. Fan
JNCI Journal of the National Cancer Institute. 2013;
[Pubmed]  [Google Scholar] [DOI]
18 Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer
Petros D. Grivas,Diane M. Robins,Maha Hussain
Critical Reviews in Oncology/Hematology. 2013; 85(1): 82
[Pubmed]  [Google Scholar] [DOI]
19 Maximizing the quantitative accuracy and reproducibility of Förster resonance energy transfer measurement for screening by high throughput widefield microscopy
Fred Schaufele
Methods. 2013;
[Pubmed]  [Google Scholar] [DOI]
20 CaMKK2: a novel target for shaping the androgen-regulated tumor ecosystem
Luigi Racioppi
Trends in Molecular Medicine. 2013; 19(2): 83
[Pubmed]  [Google Scholar] [DOI]
21 PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer
G. L. Gravina,F. Marampon,P. Muzi,A. Mancini,M. Piccolella,P. Negri-Cesi,M. Motta,A. Lenzi,E. Di Cesare,V. Tombolini,E. A. Jannini,C. Festuccia
Endocrine Related Cancer. 2013; 20(3): 321
[Pubmed]  [Google Scholar] [DOI]
22 Exercise does not counteract the effects of a westernized diet on prostate Cancer Xenografts
Vandersluis, A.D. and Venier, N.A. and Colquhoun, A.J. and Sugar, L. and Pollak, M. and Kiss, A. and Fleshner, N.E. and Klotz, L.H. and Venkateswaran, V.
Prostate. 2013; 73(11): 1223-1232
[Pubmed]  [Google Scholar]
23 Chemotherapy and targeted therapies: Are we making progress in castrate-resistant prostate cancer?
Hoffman-Censits, J. and Fu, M.
Seminars in Oncology. 2013; 40(3): 361-374
[Pubmed]  [Google Scholar]
24 A Versatile, Bar-Coded Nuclear Marker/Reporter for Live Cell Fluorescent and Multiplexed High Content Imaging
Krylova, I. and Kumar, R.R. and Kofoed, E.M. and Schaufele, F.
PLoS ONE. 2013; 8(5)
[Pubmed]  [Google Scholar]
25 The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy
Fiandalo, M.V. and Wu, W. and Mohler, J.L.
Current Drug Targets. 2013; 14(4): 420-440
[Pubmed]  [Google Scholar]
26 PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer
Gravina, G.L. and Marampon, F. and Muzi, P. and Mancini, A. and Piccolella, M. and Negri-Cesi, P. and Motta, M. and Lenzi, A. and Cesare, E.D. and Tombolini, V. and Jannini, E.A. and Festuccia, C.
Endocrine-Related Cancer. 2013; 20(3): 321-337
[Pubmed]  [Google Scholar]
27 Androgen receptors in early and castration resistant prostate cancer: Friend or foe?
Pelekanou, V. and Notas, G. and Stathopoulos, E.N. and Castanas, E. and Kampa, M.
Hormones. 2013; 12(2): 224-235
[Pubmed]  [Google Scholar]
28 Androgen Signaling Promotes Translation of TMEFF2 in Prostate Cancer Cells via Phosphorylation of the α Subunit of the Translation Initiation Factor 2
Overcash, R.F. and Chappell, V.A. and Green, T. and Geyer, C.B. and Asch, A.S. and Ruiz-Echevarría, M.J.
PLoS ONE. 2013; 8(2)
[Pubmed]  [Google Scholar]
29 CaMKK2: A novel target for shaping the androgen-regulated tumor ecosystem
Racioppi, L.
Trends in Molecular Medicine. 2013; 19(2): 83-88
[Pubmed]  [Google Scholar]
30 Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
He, S. and Zhang, C. and Shafi, A.A. and Sequeira, M. and Acquaviva, J. and Friedland, J.C. and Sang, J. and Smith, D.L. and Weigel, N.L. and Wada, Y. and Proia, D.A.
International Journal of Oncology. 2013; 42(1): 35-43
[Pubmed]  [Google Scholar]
31 Proliferative action of the androgen receptor in human uterine myometrial cells - A key regulator for myometrium phenotype programming
Liu, L. and Li, Y. and Xie, N. and Shynlova, O. and Challis, J.R.G. and Slater, D. and Lye, S. and Dong, X.
Journal of Clinical Endocrinology and Metabolism. 2013; 98(1): 218-227
[Pubmed]  [Google Scholar]
32 Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer
Grivas, P.D. and Robins, D.M. and Hussain, M.
Critical Reviews in Oncology/Hematology. 2013; 85(1): 82-93
[Pubmed]  [Google Scholar]
33 Cardiometabolic complications after androgen deprivation therapy in a man with prostate cancer: Effects of 3 years intermittent testosterone supplementation
Aversa, A. and Francomano, D. and Lenzi, A.
Frontiers in Endocrinology. 2012; 3(FEB)
[Pubmed]  [Google Scholar]
34 Factors modifying transcriptional regulation of signaling genes have putative role in tumor development and progression in humans
Qidwai, M.T. and Jamal, F. and Singh, D. and Sharma, R.K.
Medical Hypotheses. 2012; 79(6): 805-812
[Pubmed]  [Google Scholar]
35 Genomic and epigenomic alterations in prostate cancer
Aschelter, A.M. and Giacinti, S. and Caporello, P. and Marchetti, P.
Frontiers in Endocrinology. 2012; 3(NOV)
[Pubmed]  [Google Scholar]
36 Nuclear export signal of androgen receptor (NESAR) regulation of androgen receptor level in human prostate cell lines via ubiquitination and proteasome-dependent degradation
Gong, Y. and Wang, D. and Dar, J.A. and Singh, P. and Graham, L. and Liu, W. and Ai, J. and Xin, Z. and Guo, Y. and Wang, Z.
Endocrinology. 2012; 153(12): 5716-5725
[Pubmed]  [Google Scholar]
37 Obesity, energy balance, and cancer: New opportunities for prevention
Hursting, S.D. and DiGiovanni, J. and Dannenberg, A.J. and Azrad, M. and LeRoith, D. and Demark-Wahnefried, W. and Kakarala, M. and Brodie, A. and Berger, N.A.
Cancer Prevention Research. 2012; 5(11): 1260-1272
[Pubmed]  [Google Scholar]
38 Molecular Phenotyping of Immune Cells from Young NOD Mice Reveals Abnormal Metabolic Pathways in the Early Induction Phase of Autoimmune Diabetes
Wu, J. and Kakoola, D.N. and Lenchik, N.I. and Desiderio, D.M. and Marshall, D.R. and Gerling, I.C.
PLoS ONE. 2012; 7(10)
[Pubmed]  [Google Scholar]
39 Androgen receptor serine 81 mediates Pin1 interaction and activity
La Montagna, R. and Caligiuri, I. and Maranta, P. and Lucchetti, C. and Esposito, L. and Paggi, M.G. and Toffoli, G. and Rizzolio, F. and Giordano, A.
Cell Cycle. 2012; 11(18): 3415-3420
[Pubmed]  [Google Scholar]
40 Phenotypic Characterization of Prostate Cancer LNCaP Cells Cultured within a Bioengineered Microenvironment
Sieh, S. and Taubenberger, A.V. and Rizzi, S.C. and Sadowski, M. and Lehman, M.L. and Rockstroh, A. and An, J. and Clements, J.A. and Nelson, C.C. and Hutmacher, D.W.
PLoS ONE. 2012; 7(9)
[Pubmed]  [Google Scholar]
41 Temporal changes in the pathologic assessment of prostate cancer
Lucia, M.S. and Bokhoven, A.V.
Journal of the National Cancer Institute - Monographs. 2012; (45): 157-161
[Pubmed]  [Google Scholar]
42 Wnt/β 2-catenin signalling in prostate cancer
Kypta, R.M. and Waxman, J.
Nature Reviews Urology. 2012; 9(8): 418-428
[Pubmed]  [Google Scholar]
43 Role of β-arrestins mediated signaling pathways in the development of malignant tumor
Hu, S.-S. and Sun, W.-Y. and Wei, W.
Chinese Pharmacological Bulletin. 2012; 28(8): 1037-1042
[Pubmed]  [Google Scholar]
44 Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression
Godoy, A.S. and Sotomayor, P.C. and Villagran, M. and Yacoub, R. and Montecinos, V.P. and McNerney, E.M. and Moser, M. and Foster, B.A. and Onate, S.A.
Biochemical and Biophysical Research Communications. 2012; 423(3): 564-570
[Pubmed]  [Google Scholar]
45 A Hoxb13-driven reverse tetracycline transactivator system for conditional gene expression in the prostate
Rao, V. and Heard, J.C. and Ghaffari, H. and Wali, A. and Mutton, L.N. and Bieberich, C.J.
Prostate. 2012; 72(10): 1045-1051
[Pubmed]  [Google Scholar]
46 Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation
Chen, S. and Gulla, S. and Cai, C. and Balk, S.P.
Journal of Biological Chemistry. 2012; 287(11): 8571-8583
[Pubmed]  [Google Scholar]
47 Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression
Alejandro S. Godoy,Paula C. Sotomayor,Marcelo Villagran,Rami Yacoub,Viviana P. Montecinos,Eileen M. McNerney,Michael Moser,Barbara A. Foster,Sergio A. Onate
Biochemical and Biophysical Research Communications. 2012; 423(3): 564
[Pubmed]  [Google Scholar] [DOI]
48 Temporal Changes in the Pathologic Assessment of Prostate Cancer
M. S. Lucia,A. v. Bokhoven
JNCI Monographs. 2012; 2012(45): 157
[Pubmed]  [Google Scholar] [DOI]
49 Androgen receptor serine 81 mediates Pin1 interaction and activity
Raffaele La Montagna,Isabella Caligiuri,Pasquale Maranta,Chiara Lucchetti,Luca Esposito,Marco G. Paggi,Giuseppe Toffoli,Flavio Rizzolio,Antonio Giordano
Cell Cycle. 2012; 11(18): 3415
[Pubmed]  [Google Scholar] [DOI]
50 Factors modifying transcriptional regulation of signaling genes have putative role in tumor development and progression in humans
M. Tabish Qidwai,Farrukh Jamal,Dharmendrapal Singh,Ratnesh K. Sharma
Medical Hypotheses. 2012; 79(6): 805
[Pubmed]  [Google Scholar] [DOI]
51 Wnt/ß-catenin signalling in prostate cancer
Robert M. Kypta,Jonathan Waxman
Nature Reviews Urology. 2012; 9(8): 418
[Pubmed]  [Google Scholar] [DOI]


Read this article